Podcasts about UPMC

JCO PO author Dr. Foldi at UPMC Hillman Cancer Center and University of Pittsburgh School of Medicine shares insights into the JCO PO article, "Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasive Lobular Carcinoma of the Breast." Host Dr. Rafeh Naqash and Dr. Foldi discuss how serial ctDNA testing in patients with mILC is feasible and may enable personalized surveillance and real-time therapeutic monitoring. TRANSCRIPT Dr. Rafeh Naqash: Hello, and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I am your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and Associate Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, we are thrilled to be joined by Dr. Julia Foldi, Assistant Professor of Medicine in the Division of Hematology-Oncology at University of Pittsburgh School of Medicine and the Magee-Womens Hospital of the UPMC. She is also the lead and corresponding author of the JCO Precision Oncology article entitled "Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients with Metastatic Invasive Lobular Carcinoma of the Breast." At the time of this recording, our guest's disclosures will be linked in the transcript. Julia, welcome to our podcast, and thank you for joining us today. Dr. Julia Foldi: Thank you so much for having me. It is a pleasure. Dr. Rafeh Naqash: Again, your manuscript and project address a few interesting things, so we will start with the basics, since we have a broad audience that comprises trainees, community oncologists, and obviously precision medicine experts as well. So, let us start with invasive lobular breast carcinoma. I have been out of fellowship for several years now, and I do not know much about invasive lobular carcinoma. Could you tell us what it is, what some of the genomic characteristics are, why it is different, and why it is important to have a different way to understand disease biology and track disease status with this type of breast cancer? Dr. Julia Foldi: Yes, thank you for that question. It is really important to frame this study. So, lobular breast cancers, which we shorten to ILC, are the second most common histologic subtype of breast cancer after ductal breast cancers. ILC makes up about 10 to 15 percent of all breast cancers, so it is relatively rare, but in the big scheme of things, because breast cancer is so common, this represents actually over 40,000 new diagnoses a year in the US of lobular breast cancers. What is unique about ILC is it is characterized by loss of an adhesion molecule, E-cadherin. It is encoded by the CDH1 gene. What it does is these tumors tend to form discohesive, single-file patterns and infiltrate into the tumor stroma, as opposed to ductal cancers, which generally form more cohesive masses. As we generally explain to patients, ductal cancers tend to form lumps, while lobular cancers often are not palpable because they infiltrate into the stroma. This creates several challenges, particularly when it comes to imaging. In the diagnostic setting, we know that mammograms and ultrasounds have less sensitivity to detect lobular versus ductal breast cancer. When it comes to the metastatic setting, conventional imaging techniques like CT scans have less sensitivity to detect lobular lesions often. One other unique characteristic of ILC is that these tumors tend to have lower proliferation rates. Because our glucose-based PET scans depend on glucose uptake of proliferating cells, often these tumors also are not avid on conventional FDG-PET scans. It is a challenge for us to monitor these patients as they go through treatment. If you think about the metastatic setting, we start a new treatment, we image people every three to four cycles, about every three months, and we combine the imaging results with clinical assessment and tumor markers to decide if the treatment is working. But if your imaging is not reliable, sometimes even at diagnosis, to really detect these tumors, then really, how are we following these patients? This is really the unique challenge in the metastatic setting in patients with lobular breast cancer: we cannot rely on the imaging to tell if patients are responding to treatment. This is where liquid biopsies are really, really important, and as the field is growing up and we have better and better technologies, lobular breast cancer is going to be a field where they are going to play an important role. Dr. Rafeh Naqash: Thank you for that easy-to-understand background. The second aspect that I would like to have some context on, to help the audience understand why you did what you did, is ctDNA, tumor informed and non-informed. Could you tell us what these subtypes of liquid biopsies are and why you chose a tumor informed assay for your study? Dr. Julia Foldi: Yes, it is really important to understand these differences. As you mentioned, there are two main platforms for liquid biopsy assays, circulating tumor DNA assays. I think what is more commonly used in the metastatic setting are non-tumor informed assays, or agnostic assays. These are generally next-generation sequencing-based assays that a lot of companies offer, like Guardant, Tempus, Caris, and FoundationOne. These do not require tumor tissue; they just require a blood sample, a plasma sample, essentially. The next-generation sequencing is done on cell-free DNA that is extracted from the plasma, and it is looking for any cell-free DNA and essentially, figuring out what part of the cell-free DNA comes from the tumor is done through a bioinformatics approach. Most of these assays are panel tests for cancer-associated mutations that we know either have therapeutic significance or biologic significance. So, the results we receive from these tests generally read out specific mutations in oncogenic genes, or sometimes things like fusions where we have specific targeted drugs. Some of the newer assays can also read out tumor fraction; for example, the newest generation Guardant assay that is methylation-based, they can also quantify tumor fraction. But the disadvantage of the tumor agnostic approach is that it is a little bit less sensitive. Opposed to that, we have our tumor informed tests, and these require tumor tissue. Essentially, the tumor is sequenced; this can either be whole exome or whole genome sequencing. The newer generation assays are now using whole genome sequencing of the tumor tissue, and a personalized, patient-specific panel of alterations is essentially barcoded on that tumor tissue. This can be either structural variants or it can be mutations, but generally, these are not driver mutations, but sort of things that are present in the tumor tissue that tend to stay unchanged over time. For each particular patient, a personalized assay, if you want to call it a fingerprint or barcode, is created, and then that is what then is used to test the plasma sample. Essentially, you are looking for that specific cancer in the blood, that barcode or fingerprint in the blood. Because of this, this is a much more sensitive way of looking for ctDNA, and obviously, this detects only that particular tumor that was sequenced originally. So, it is much more sensitive and specific to that tumor that was sequenced. You can argue for both approaches in different settings. We use them in different settings because they give us different information. The tumor agnostic approach gives us mutations, which can be used to determine what the next best therapy to use is, while the tumor informed assay is more sensitive, but it is not going to give us information on therapeutic targets. However, it is quantified, and we can follow it over time to see how it changes. We think that it is going to tell us how patients respond to treatment because we see our circulating tumor DNA levels rise and fall as the cancer burden increases or decreases. We decided to use the tumor informed approach in this particular study because we were really interested in how to determine if patients are having response to treatment versus if they are going to progress on their treatment, more so than looking for specific mutations. Dr. Rafeh Naqash: When you think about these tumor informed assays and you think about barcoding the mutations on the original tumor that you try to track or follow in subsequent blood samples, plasma samples, in your experience, if you have done it in non-lobular cancers, do you think shedding from the tumor has something to do with what you capture or how much you capture? Dr. Julia Foldi: Absolutely. I think there are multiple factors that go into whether someone has detectable ctDNA or not, and that has to do with the type of cancer, the location, right, where is the metastatic site? This is something that we do not fully understand yet: what are tumors that shed more versus not? There is also clearance of ctDNA, and so how fast that clearance occurs is also something that will affect what you can detect in the blood. ctDNA is very short-lived, only has a half-life of hours, and so you can imagine that if there is little shedding and a lot of excretion, then you are not going to be detecting a lot of it. In general, in the metastatic setting, we see that we can detect ctDNA in a lot of cases, especially when patients are progressing on treatment, because we imagine their tumor burden is higher at that point. Even with the non-tumor informed assays, we detect a lot of ctDNA. Part of this study was to actually assess: what is the proportion of patients where we can have this information? Because if we are only going to be able to detect ctDNA in less than 50 percent of patients, then it is not going to be a useful method to follow them with. Because this field is new and we have not been using a lot of tumor informed assays in the metastatic setting, we did not really know what to expect when we set out to look at this. We did not know what was going to be the baseline detection rate in this patient population, so that was one of the first things that we wanted to answer. Dr. Rafeh Naqash: Excellent. Now going to this manuscript in particular, what was the research question, what was the patient population, and what was the strategy that you used to investigate some of these questions? Dr. Julia Foldi: So, we partnered with Natera, and the reason was that their Signatera tumor-informed assay was the first personalized, tumor-informed, really an MRD assay, minimal residual disease detection assay. It has been around the longest and has been pretty widely used commercially already, even though some of our data is still lacking. but we know that people are using this in the real world. We wanted to gather some real-world data specifically in lobular patients. So, we asked Natera to look at their database of commercial Signatera testing and look for patients with stage 4 lobular breast cancer. The information all comes from the submitting physicians sending in pathologic reports and clinical notes, and so they have that information from the requisitions essentially that are sent in by the ordering physician. We found 66 patients who were on first-line or close to first-line endocrine-based therapies for their metastatic lobular breast cancer and had serial collections of Signatera tests. The way we defined baseline was that the first Signatera had to be sent within three months of starting treatment. So, it is not truly baseline, but again, this is a limitation of looking at real-world data is that you are not always going to get the best time point that you need. We had over 350 samples from those 66 patients, again longitudinal ctDNA samples, and our first question was what is the baseline detection rate using this tumor informed assay? Then, most importantly, what is the concordance between changes in ctDNA and clinical response to treatment? That is defined by essentially radiologic response to treatment. Dr. Rafeh Naqash: Interesting. So, what were some of your observations in terms of ctDNA dynamics, whether baseline levels made a difference, whether subsequent levels at different time points made a difference, or subsequent levels at, let us say, cycle three made a difference? Were there any specific trends that you saw? Dr. Julia Foldi: So, first, at baseline, 95 percent of patients had detectable ctDNA, which is, I think, a really important data point because it tells us that this can be a really useful test. If we can detect it in almost all patients before they start treatment, we are going to be able to follow this longitudinally. And again, these were not true baseline samples. So, I think if we look really at baseline before starting treatment, almost all patients will have detectable ctDNA in the metastatic setting. The second important thing we saw was that disease progression correlated very well with increase in ctDNA. So, in most patients who had disease progression by imaging, we saw increase in ctDNA. Conversely, in most patients who had clinical benefit from their treatment, so they had a response or stable disease, we saw decrease in ctDNA levels. It seems that what we call molecular response based on ctDNA is tracking very nicely along with the radiographic response. So, those were really the two main observations. Again, this is a small cohort, limited by its real-world nature and the time points that ctDNA assay was sent was obviously not mandated. This is a real-world data set, and so we could not really look at specific time points like you asked about, let us say, cycle three of therapy, right? We did not have all of the right time points for all of the patients. But what we were able to do was to graph out some specific patient scenarios to illustrate how changes in ctDNA correlate with imaging response. I can talk a little bit about that. Dr. Rafeh Naqash: That was going to be my question. Did you see patients who had serial monitoring using the tumor informed ctDNA assay where the assay became positive a few months before the imaging? Did you have any of those kinds of observations? Dr. Julia Foldi: Yes, so I think this is where the field is going: are we able to use this technology to maybe detect progression before it becomes clinically apparent? Of course, there are lots of questions about: does that really matter? But it seems like, based on some of the patient scenarios that we present in the paper, that this testing can do that. So, we had a specific scenario, and this is illustrated in a figure in the paper, really showing the treatment as well as the changes in ctDNA, tumor markers, and also radiographic response. So, this particular patient was on first-line endocrine therapy and CDK4/6 inhibitor with palbociclib. Initially, she had a low-level detectable ctDNA. It became undetectable during treatment, and the patient had a couple of serial ctDNA assays that were negative, so undetectable. And then we started, after about seven months on this combination therapy, the ctDNA levels started rising. She actually had three serial ctDNA assays with increasing level of ctDNA before she even had any imaging tests. And then around the time that the ctDNA peaked, this patient had radiographic evidence of progression. There was also an NGS-based assay sent to look for specific mutations at that point. The patient was found to have an ESR1 mutation, which is very common in this patient population. She was switched to a novel oral SERD, elacestrant, and the ctDNA fell again to undetectable within the first couple months of being on elacestrant. And then a very similar thing happened: while she was on this second-line therapy, she had three serial negative ctDNA assays, and then the fourth one was positive. This was two months before the patient had a scan that showed progression again. Dr. Rafeh Naqash: And Julia, like you mentioned, this is a small sample size, limited number of patients, in this case, one patient case scenario, but provides insights into other important aspects around escalation or de-escalation of therapy where perhaps ctDNA could be used as an integral biomarker rather than an exploratory biomarker. What are some of your thoughts around that and how is the breast cancer space? I know like in GI and bladder cancer, there has been a significant uptrend in MRD assessments for therapeutic decision making. What is happening in the breast cancer space? Dr. Julia Foldi: So, super interesting. I think this is where a lot of our different fields are going. In the breast cancer space, so far, I have seen a lot of escalation attempts. It is not even necessarily in this particular setting where we are looking at dynamics of ctDNA, but in the breast cancer world, of course, we have a lot of data on resistance mutations. I mentioned ESR1 mutation in a particular patient in our study. ESR1 mutations are very common in patients with ER-positive breast cancer who are on long-term endocrine therapy, and ESR1 mutations confer resistance to aromatase inhibitors. So, that is an area that there has been a lot of interest in trying to detect ESR1 mutations earlier and switching therapy early. So, this was the basis of the SERENA-6 trial, which was presented last year at ASCO and created a lot of excitement. This was a trial where patients had non-tumor-informed NGS-based Guardant assay sent every three to six months while they were on first-line endocrine therapy with a CDK4/6 inhibitor. If they had an ESR1 mutation detected, they were randomized to either continue the same endocrine therapy or switch to an oral SERD. The trial showed that the population of patients who switched to the oral SERD did better in terms of progression-free survival than those who stayed on their original endocrine therapy. There are a lot of questions about how to use this in routine practice. Of course, it is not trivial to be sending a ctDNA assay every three to six months. The rate of detection of these mutations was relatively low in that study; again, the incidence increases in later lines of therapy. So, there are a lot of questions about whether we should be doing this in all of our first-line patients. The other question is, even the patients who stayed on their original endocrine therapy were able to stay on that for another nine months. So, there is this question of: are we switching patients too early to a new line of therapy by having this escalation approach? So, there are a lot of questions about this. As far as I know, at least in our practice, we are not using this approach just yet to escalate therapy. Time will tell how this all pans out. But I think what is even more interesting is the de-escalation question, and I think that is where tumor informed assays like Signatera and the data that our study generated can be applied. Actually, our plan is to generate some prospective data in the lobular breast cancer population, and I have an ongoing study to do that, to really be able to tease out the early ctDNA dynamics as patients first start on endocrine therapy. So, this is patients who are newly diagnosed, they are just starting on their first-line endocrine therapy, and measure, with sensitive assays, measure ctDNA dynamics in the first few months of therapy. In those patients who have a really robust response, that is where I think we can really think about de-escalation. In the patients whose ctDNA goes to undetectable after just a few weeks of therapy with just an endocrine agent, they might not even need a CDK4/6 inhibitor in their first-line treatment. So, that is an area where we are very interested in our group, and I know that other groups are looking at this too, to try to de-escalate therapy in patients who clear their ctDNA early on. Dr. Rafeh Naqash: Thank you so much. Well, lots of questions, but at the same time, progress comes through questions asked, and your project is one of those which is asking an interesting question in a rarer cancer and perhaps will lead to subsequent improvement in how we monitor these individuals and how we escalate or de-escalate therapy. Hopefully, we will get to see more of what you are working on in subsequent submissions to JCO Precision Oncology and perhaps talk more about it in a couple of years and see how the space and field is moving. Thanks again for sharing your insights. I do want to take one to two quick minutes talking about you as an investigator, Julia. If you could speak to your career pathway, your journey, the pathway to mentorship, the pathway to being a mentor, and how things have shaped for you in your personal professional growth. Dr. Julia Foldi: Sure, yeah, that is great. Thank you. So, I had a little bit of an unconventional path to clinical medicine. I actually thought I was going to be a basic scientist when I first started out. I got a PhD in Immunology right out of college and was studying not even anything cancer-related. I was studying macrophage signaling in inflammatory diseases, but I was in New York City. This was right around the time that the first checkpoint inhibitors were approved. Actually, some of my friends from my PhD program worked in Jim Allison's lab, who was the basic scientist responsible for ipilimumab. So, I got to kind of first-hand experience the excitement around bringing something from the lab into the clinic that actually changed really the course of oncology. And so, I got very excited about oncology and clinical medicine. So, I decided to kind of switch gears from there and I went back to medical school after finishing my PhD and got my MD at NYU. I knew I wanted to do oncology, so I did a research track residency and fellowship combined at Yale. I started working early on with the breast cancer team there. At the time, Lajos Pusztai was the head of translational research there at Yale, and I started working with him early in my residency and then through my fellowship. I worked on several trials with him, including a neoadjuvant checkpoint inhibitor trial in triple-negative breast cancer patients. During my last year in fellowship, I received a Conquer Cancer Young Investigator Award to study estrogen receptor heterogeneity using spatial transcriptomics in this subset of breast cancers that have intermediate estrogen receptor expression. From there, I joined the faculty at the University of Pittsburgh in 2022. So, I have been there about almost four years at this point. My interests really shifted slowly from triple-negative breast cancers towards ER-positive breast cancers. When I arrived in Pittsburgh, I started working very closely with some basic and translational researchers here who are very interested in estrogen signaling and mechanisms of resistance to endocrine therapy, and there is a large group here interested in lobular breast cancers. During my training, I was not super aware even that lobular breast cancer was a unique subtype of breast cancers, and that is, I think, changing a little bit. There is a lot more awareness in the breast cancer clinical and research community about ILC being a unique subtype, but it is not even really part of our training in fellowship, which we are trying to change. But I have become a lot more aware of this because of the research team here and through that, I have become really interested also on the clinical side. And so, we do have a Lobular Breast Cancer Research Center of Excellence here at the University of Pittsburgh and UPMC, and I am the leader on the clinical side. We have a really great team of basic and translational researchers looking at different aspects of lobular breast cancers, and some of the work that I am doing is related to this particular manuscript we discussed and the next steps, as I mentioned, a prospective study of early ctDNA dynamics in lobular patients. I also did some more clinical research work in collaboration with the NSABP looking at long-term outcomes of patients with lobular versus ductal breast cancers in some of their older trials. And so, that is, in a nutshell, a little bit about how I got here and how I became interested in ILC. Dr. Rafeh Naqash: Well, thank you for sharing those personal insights and personal journey. I am sure it will inspire other trainees, fellows, and perhaps junior faculty in trying to find their niche. The path, as you mentioned, is not always straight; it often tends to be convoluted. And then finding an area that you are interested in, taking things forward, and being persistent is often what matters. Dr. Julia Foldi: Thank you so much for having me. It was great. Dr. Rafeh Naqash: It was great chatting with you. And thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Join us for a compelling conversation with award-winning journalist and bestselling writer Wil Haygood (author of The Butler) as he discusses his latest book, The War Within a War: The Black Struggle in Vietnam and at Home (out February 10, 2026). Haygood reframes the Vietnam War not simply as a foreign conflict, but as a crucible in which the fight for civil rights followed Black Americans from the streets of the United States into the jungles of Southeast Asia. Drawing on deep research and vivid personal stories, he traces the lives of Black soldiers, airmen, doctors, nurses, journalists, and activists who fought simultaneously against enemy forces abroad and systemic racism at home. In The War Within a War, readers encounter figures both famous and obscure: from an Air Force pilot POW and a frontline surgeon to Marvin Gaye and Martin Luther King, Jr. The goal is to illuminate how this dual struggle reshaped both the war and the American conscience. This book goes beyond military history to explore how race and war intersected in ways that still echo in American life. Haygood's narrative brings urgency and humanity to a chapter of the Vietnam era that reshapes our understanding of service, sacrifice, and the unfinished fight for equality. Join us to hear from one of America's most insightful chroniclers of Black experience and national history, and to engage with the stories that still reverberate a half-century later. We're grateful to UPMC for Life  for sponsoring this event!

Join me as I speak with UPMC research physician Ken Urish about innovations in surgery, how surgery practices translate into everyday life, and more. Ken also reminds us to enjoy the little things, like being able to walk a half a mile without being in physical pain.Liked this episode and want to see or hear more? Please subscribe to Collaborative with Spencer Krause today. You'll get notified every time a new episode releases, and it's the best way to support the channel! Businesses looking to outsource difficult robotics engineering problems should consider SKA Robotics. They sponsor this podcast and solve some of the most difficult robotics engineering problems in the world. Companies looking for premium space in Pittsburgh should consider renting in Rockwell Park. Located in Pittsburgh's hip Point Breeze Neighborhood, Rockwell Park features over 800,000 square feet of high-end industrial, retail, and office space. Contact Icon Development Group to learn more.

Join me as I speak with UPMC research physician Ken Urish about innovations in surgery, how surgery practices translate into everyday life, and more. Ken also reminds us to enjoy the little things, like being able to walk a half a mile without being in physical pain.Liked this episode and want to see or hear more? Please subscribe to Collaborative with Spencer Krause today. You'll get notified every time a new episode releases, and it's the best way to support the channel! Businesses looking to outsource difficult robotics engineering problems should consider SKA Robotics. They sponsor this podcast and solve some of the most difficult robotics engineering problems in the world. Companies looking for premium space in Pittsburgh should consider renting in Rockwell Park. Located in Pittsburgh's hip Point Breeze Neighborhood, Rockwell Park features over 800,000 square feet of high-end industrial, retail, and office space. Contact Icon Development Group to learn more.

It's tax season… but not for our city's largest nonprofits, aka the Big Five. Mayor Corey O'Connor got some big wins with a pair of one-time donations from UPMC and PNC Bank's foundation last week, but what happens now? Our health care giants and major universities — UPMC, Highmark Health, the University of Pittsburgh, Carnegie Mellon University, and Duquesne University — collectively own about one-eighth of all the land in Pittsburgh. But because PA law considers them "purely public charities," they  don't have to pay property taxes like the rest of us. Host Megan Harris and executive producer Mallory Falk are talking about the rage people feel about that, how the courts created this mess, and various local efforts over the years to get these big nonprofits to "pay their fair share."  Have any special insight into negotiations with the nonprofits before the 2000s? Call or text our HOW DID THIS HAPPEN? HOTLINE at 412-212-8893. Learn more about the sponsor of this February 5th episode: P3R - Use code CITYCAST15 to save 15% off any event registration Become a member of City Cast Pittsburgh at membership.citycast.fm. Want more Pittsburgh news?  Sign up for our daily morning Hey Pittsburgh newsletter. We're on Instagram @CityCastPgh. Text or leave us a voicemail at 412-212-8893. Interested in advertising with City Cast? Find more info here. 

On this episode of the Project Purple Podcast, host Dino Verrelli sits down with Andy Lyons, a commercial photographer from the heart of the Midwest, Iowa, as he shares his deeply personal journey with familial pancreatic cancer. With a family history spanning three generations, affecting countless family members, including his grandmother, mother, and brother, Andy has long felt the shadow of this disease. Diagnosed in 2021 after over two decades of proactive screenings, including ultrasound endoscopies and genetic testing through research studies in Chicago and Pittsburgh, Andy was fortunate to catch his pancreatic cancer early. He reflects on the importance of vigilance and early detection, and how his experience demonstrates the power of knowledge, community, and persistence in managing a disease often considered a death sentence, even when it runs in your family. Andy shares the emotional and practical aspects of his journey: robotic surgery at UPMC, chemotherapy, the support of caregivers and his community, and the mental resilience that comes from maintaining humor, positivity, and hope. He emphasizes the importance of asking questions, connecting with other patients, and taking control of your health, summarized in the motto: “knowledge is power.” Through his story, Andy shows that pancreatic cancer is scary, but it's not invincible. He talks about the strength found in numbers, the hope that comes from proactive care, and even the symbolic meaning of a survivor tattoo and a healing blanket passed among friends as a gesture of solidarity. You can reach Andy at andyboylyons@gmail.com. Subscribe to the Project Purple Podcast for more stories from the pancreatic cancer community. To learn more or support Project Purple's mission of a world without pancreatic cancer, visit projectpurple.org.

Dr. Donald Yealy (Chief Medical officer UPMC) joins the show to talk about the weather and the impact on the numbers of people falling

Join the Veterans Breakfast Club for an open and wide-ranging virtual conversation about the military experience, past and present. We believe every veteran has a story to tell and wisdom to share. This event is a chance to listen, learn, and connect with others who understand the unique bonds and challenges of military service. If you have something on your mind—whether a personal memory, a question, or a topic you think deserves attention—we encourage you to bring it to the conversation. Veterans are also invited to email Shaun Hall at shaun@veteransbreakfastclub.org with any specific topics or issues they'd like to discuss. The Veterans Breakfast Club's mission is to create communities of listening around veterans and their stories, and our Open Conversations are one of the most dynamic ways we do that. These sessions are often wide-ranging, emotional, funny, and thought-provoking, providing a welcoming space where everyone's voice is valued. This event is free and open to all. To join the conversation live on Zoom, please use this link: https://us02web.zoom.us/j/6402618738. Or tune in on Facebook or YouTube at 7:00pm ET on February 2. Whether you have something to share or simply want to listen and learn, we welcome you to be part of the conversation! We're grateful to UPMC for Life  for sponsoring this event!

In this "Giants in Plastic Surgery" episode of the PRS Global Open Deep Cuts Podcast, we sit down with Dr. Andrea Moreira, renowned plastic surgeon, breast reconstruction expert, and global health advocate, to explore the remarkable journey behind her career and the wisdom she's gained along the way. Dr. Moreira shares the personal story behind why she chose medicine, what it was like training at the University of Pará in Brazil, and the emotional and professional challenges of repeating medical school after moving to the United States. She walks us through the differences she observed between residency training in Brazil and the U.S., her path through two residencies at the Cleveland Clinic, and her progression into leadership roles at major institutions including the Cleveland Clinic and UPMC, where she now serves as Director of Innovation for Breast Reconstruction Services and Chief of Plastic Surgery at Magee Women's Hospital. We dive into her cutting-edge work in robotic-assisted microsurgery, breast neurotization, and direct-to-implant reconstruction, as well as her experiences in research, teaching, and global health missions. Dr. Moreira also opens up about the mentors who shaped her career, how she and her husband navigate life as a dual-physician couple, and how trainees can identify the right program or environment for their stage of development. Whether you're a medical student, resident, or aspiring plastic surgeon, Dr. Moreira offers thoughtful advice on when, and how, to get involved, the value of microsurgery training, and what she wishes more young surgeons knew. A candid, inspiring conversation with one of the field's most forward-thinking leaders. Read a recent classic PRS Global Open article by Dr. Moreira and co-authors, "Learning Curve Analysis for Robotic-assisted Harvest of Deep Inferior Epigastric Perforator Flap": https://bit.ly/Robotic_DIEP_GOX   Your host, Dr. Vimal Gokani, is a senior Specialty Registrar in plastic surgery in London, England. Your producer & editor, Charlene Kok, is a Year 4 Medical Student in Imperial College London, England, with a keen interest in Plastic Surgery.  #PRSGlobalOpen #DeepCutsPodcast #PlasticSurgery #GiantsPlasticSurgery

Some of our streets still haven't been cleared, nearly a week after the Pittsburgh region was hit with double digit snowfall. When can we expect some relief? And will UPMC's $10 million gift for emergency vehicles make things better? (Also, just how generous is this gift, really?) City Cast Pittsburgh host Megan Harris is joined by producer Sophia Lo and contributor Colin Williams to share the latest on snow removal. Plus, they discuss city and county efforts to restrict ICE activity, whether the new Steelers head coach counts as a win or loss for our city, and how you can help make a Pittsburgh-themed Lego set become a reality. Notes and references from today's show: UPMC gives $10M to city for plows, ambulances [Axios Pittsburgh] The challenges Pittsburgh Regional Transit faced before making rare decision to suspend service during snowstorm [Post-Gazette] Pittsburgh-area school districts are running out of snow days [KDKA] PODCAST: Mayor O'Connor on ICE, Affordability & AI [City Cast Pittsburgh] PODCAST: Can You Be Charged for Getting in ICE's Way? [City Cast Pittsburgh] Ways To Support Pittsburgh's Immigrant Communities [City Cast Pittsburgh] 'Pittsburgh is my world': Emotional Mike McCarthy introduced as new Steelers coach [Post-Gazette] Guild Journalists, Pittsburgh Community, Local Labor Comes Together to Launch PAPER [CWA] Architecture: Pittsburgh, Pennsylvania [Lego Ideas] Who Should Be On Pittsburgh's Walk of Fame? [City Cast Pittsburgh] Walk of Fame Nominations [Pittsburgh Walk of Fame] Learn more about the sponsors of this January 30th episode: Fulton Commons The Westmoreland Museum P3R Planned Parenthood of Western Pennsylvania Become a member of City Cast Pittsburgh at membership.citycast.fm. Want more Pittsburgh news? Sign up for our daily morning newsletter. We're also on Instagram @CityCastPgh! Interested in advertising with City Cast? Find more info here.

Pittsburgh Mayor held a news conference to announce a $10 million donation.

Join the Veterans Breakfast Club for a powerful livestream conversation with Michael Archer, U.S. Marine Corps veteran and author of A Patch of Ground: Khe Sanh, a firsthand account of one of the most intense and contested battles of the Vietnam War. Michael Archer is not writing as a distant historian or outside observer. He was a Marine at Khe Sanh. He lived on that patch of ground, endured the siege, and carried its weight with him long after leaving Vietnam. His book is rooted in direct experience—what it meant to be young, scared, exhausted, and determined, holding a remote combat base under constant artillery fire while the world debated whether Khe Sanh would become another Dien Bien Phu. A Patch of Ground is spare, unsentimental, and deeply personal. Archer writes about daily life under siege: patrols, bunkers, incoming rounds, boredom and terror existing side by side, and the bonds formed among Marines who depended on one another to survive. He also writes about memory—how Khe Sanh stayed with him, how veterans carry places like that inside them, and why telling the story matters decades later. In this conversation, we'll focus squarely on Archer's Marine Corps service and his experience at Khe Sanh: what he remembers, what surprised him looking back, and what gets lost when battles are reduced to maps, timelines, and strategic arguments. We'll talk about why Khe Sanh became such a symbol during the war, what it felt like on the ground to be part of that symbol, and how writing the book helped Archer make sense of an experience that never really ends. This is a conversation about combat, memory, and bearing witness—told by a Marine who was there, on that ground, and who has spent years finding the words to describe it. We're grateful to UPMC for Life  for sponsoring this event!

Marty opens the show speaking with Kristine (KDKA) and Dr. Donald Yealy (Chief Medical officer UPMC) about the weather and the impact it can have on your health

In this Veterans Breakfast Club livestream, we sit down with filmmaker Steven Grayhm to talk about Sheepdog, an independent feature film that takes a hard, honest look at combat trauma, recovery, and the long road home. Grayhm not only stars in the film, but also wrote, produced, and directed it—an unusual level of authorship that reflects how personal the project is. Sheepdog centers on Calvin Cole (Grayhm), a decorated U.S. Army combat veteran who is court-ordered into treatment and placed under the care of a VA trauma therapist-in-training (played by Madsen), who is juggling her clinical work with night shifts at a diner to pay for school. Calvin's fragile attempt to hold himself together is further tested when his father-in-law, a retired Vietnam veteran (Curtis Hall), appears at his door fresh out of prison. As Calvin's instinct to run from his past collapses, the film traces how accountability, compassion, and hard-earned trust can open a path toward healing. Shot on location in Western Massachusetts, Sheepdog aims to lift the veil on post-traumatic stress and the veteran suicide crisis, while also focusing on the often-overlooked idea of post-traumatic growth. Rather than offering easy answers, the film shows the physical and psychological consequences of trauma—and the slow, uneven work of recovery—through grounded performances and lived-in settings. Film critic Tony Toscana called it “one of the best films of the year.” We'll ask Grayhm about how Sheepdog came to be: years spent listening to veterans' stories, studying trauma and VA treatment models, and working closely with veterans and clinicians to get the details right. He'll reflect on why he felt compelled to tell this story himself, why authenticity matters more than spectacle, and what it takes to bring an independently made, veteran-centered film from script to screen. This livestream will explore the making of Sheepdog, the responsibilities of telling veterans' stories on film, and what cinema can—and cannot—do when it comes to understanding trauma, recovery, and the complicated work of coming home. We're grateful to UPMC for Life  for sponsoring this event!

Before he ever flew gunships in Vietnam or logged 900 combat hours over the Central Highlands, Gil Ferrey had already taken a remarkable detour into the frontlines of the Cold War. In the fall of 1961—just three weeks after construction began on the Berlin Wall—Gil, then a 20-year-old American student studying in East Berlin, attempted to help a young woman escape to the West. He and a friend, Victor Pankey, hid her in the trunk of their car and made a run for the border. They didn't make it. East German border guards arrested them at the crossing. What followed was four months in a state security prison, weeks of solitary confinement, a trial with a predetermined outcome, and an unexpected release reportedly granted as a personal “act of mercy” by Walter Ulbricht. The New York Times covered the case closely in 1962: two young Californians imprisoned for an act they considered morally right, even if East German law judged otherwise. When they emerged, shaggy-haired but unbroken, both said they'd been treated well. But the experience left its mark. Gil will tell the story of how a semester abroad in a sealed-off city became a collision with Communist state power and a firsthand look at the making of the Cold War's most visible boundary. But Ferrey's story doesn't end at Checkpoint Charlie. After returning home, finishing his studies at Claremont Men's College, and earning his commission, he went on to serve as an Army aviator. He trained at Fort Wolters and Fort Rucker, earned his wings in December 1964, and served first in Korea with the 7th Aviation Battalion, then stateside with the 11th Armored Cavalry Regiment. In Vietnam, Gill flew Hueys and Hiller 23G “Raven” scout helicopters, logging 900 combat hours. This is one of those rare veteran stories that opens a window not just onto a war, but onto an entire era. We're grateful to UPMC for Life  for sponsoring this event!

Join the Veterans Breakfast Club for an open and wide-ranging virtual conversation about the military experience, past and present. We believe every veteran has a story to tell and wisdom to share. This event is a chance to listen, learn, and connect with others who understand the unique bonds and challenges of military service. If you have something on your mind—whether a personal memory, a question, or a topic you think deserves attention—we encourage you to bring it to the conversation. Veterans are also invited to email Shaun Hall at shaun@veteransbreakfastclub.org with any specific topics or issues they'd like to discuss. The Veterans Breakfast Club's mission is to create communities of listening around veterans and their stories, and our Open Conversations are one of the most dynamic ways we do that. These sessions are often wide-ranging, emotional, funny, and thought-provoking, providing a welcoming space where everyone's voice is valued. This event is free and open to all. To join the conversation live on Zoom, please use this link: https://us02web.zoom.us/j/6402618738. Or tune in on Facebook or YouTube at 7:00pm ET on June 9. Whether you have something to share or simply want to listen and learn, we welcome you to be part of the conversation! We're grateful to UPMC for Life  for sponsoring this event!

Aerial photographs, weather observation and even food delivery are a few of the uses for drones. What about getting emergency medical equipment to rural areas where it’s needed, quickly? There’s now a public-private partnership aiming to use drones to do just that in central Pennsylvania. The U-S Department of Justice says it won’t require names of minors who received gender-affirming care at hospitals operated by UPMC. Patients' identities are embedded into their medical files. The holiday travel season is expected to set records. AAA estimates more than 122 million Americans will travel at least 50 miles from home between December 20th and January 1st. Pennsylvania Attorney General Dave Sunday is now serving in a leadership role among Eastern U-S attorneys general. More than 14-million dollars in grant funding is being awarded to community projects across Pennsylvania, by the state's Department of Community and Economic Development. The projects support communities in four areas: flood mitigation, recreational trails, improvements to sewage facilities and watersheds. More than 4.4 million dollars is being awarded to about 30 community projects in Dauphin County. If you're already a member of WITF's Sustaining Circle, you know how convenient it is to support programs like the Morning Agenda. By increasing your monthly gift, you can help WITF close the budget gap left by the loss of federal funding. Visit us online at witf.org/increase or become a new Sustaining Circle member at www.witf.org/givenow. Thank you.Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

One week before the Tet Offensive of 1968, a small, unarmed Navy intelligence ship called the USS Pueblo was attacked and captured by North Korea. The seizure of the Pueblo became its own crisis running parallel to Tet, trapping 82 American sailors in a struggle for survival that lasted nearly a year. One of those sailors was 20-year-old Steven Woelk from Kansas. On our upcoming VBC livestream, Steven will join us to share his remarkable firsthand story, now told in full in his soon-to-be-released memoir, Pig Fat Soup: Surviving My Pueblo Prisoner of War Journey. When cannon rounds started ripping into the lightly armed spy ship, Woelk was below decks with three shipmates, frantically trying to burn classified material before it could be captured. The smoke gave them away. A North Korean round tore through their space, killing Woelk's friend and leaving Woelk himself gravely wounded. Because of those wounds, he became the last sailor to leave the Pueblo. Carried off the ship after Commander Lloyd Bucher surrendered to prevent further slaughter, Woelk then went ten full days without medical treatment. When surgery finally came, it was brutal. Shrapnel, bone fragments, and his testicles were removed without anesthesia. He still has no idea how he survived without infection. Woelk spent forty-four days in a North Korean hospital, which spared him some of the savage beatings his crewmates endured. But nothing shielded him from “hell week,” the torture that followed once the captors discovered the crew's defiant middle-finger gesture wasn't, in fact, a friendly Hawaiian greeting. “You pray you're strong enough to resist,” he later said, “but you never know until you face that reality.” There were long stretches of boredom, hunger, and fear, punctuated by sudden terror, never knowing whether the next moment would bring a beating, execution, or, by some miracle, release. Release finally came two days before Christmas 1968. For his wounds and captivity, Woelk received two Purple Hearts and the POW Medal. The Pueblo remains the only U.S. Navy vessel still held by a foreign nation, displayed by North Korea as a trophy and propaganda exhibit. Steven Woelk has spent much of his life ensuring that the Pueblo is not forgotten. His memoir, Pig Fat Soup, offers the most detailed and candid account he's ever shared—one that moves from the chaos of the attack to the freezing bunkrooms of the “Barn,” the POW camp where the crew endured nearly a year of captivity. We're grateful to UPMC for Life  for sponsoring this event!

Marty Speaks with Maribeth McLaughlin ( Chief Nurse Executive UPMC) about a graduating class and the needed influx of nurses

The recently passed Pennsylvania state budget includes more money for tuberculosis prevention efforts in the Commonwealth. Federal data show cases of TB steadily rising nationally after nearly three decades of decline. The University of Pittsburgh Medical Center is establishing a rural residency program in an effort to bolster the rural doctor workforce. Here’s how it works: Residents start at UPMC Williamsport before transferring to either UPMC Wellsboro or UPMC Cole in Coudersport. Both locations are in Pennsylvania’s northern tier known as the Pennsylvania Wilds region. In Cumberland County, an 80-year-old woman was found dead after a house fire early Sunday morning, according to the Cumberland County Coroner's Office. State officials discovered a month's worth of mail wasn't sent by a government-contracted mail house over the past month. The backlog of mail totals 3.4 million letters, including notices of SNAP eligibility and health benefit information, as well as driver’s license and vehicle registration renewal invitations from PennDOT. Pennsylvania lawmakers could end the year with the lowest number of new laws in at least a decade. That's due to split government, heightened partisanship, and the concentration of power in the hands of legislative leaders, according to reporting by our partners at Spotlight PA. Sunday marked the beginning of Hanukkah. The city of Lancaster and the Jewish Community Alliance of Lancaster hosted a menorah lighting in Penn Square. Did you know that if every sustaining circle member gives as little as $12 more a month, we'd close the gap caused by federal funding cuts? Increase your gift at https://witf.org/increase or become a new Sustaining Circle member at www.witf.org/givenow.Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

Edward Ford and Alan Chiasson came to Afghanistan with long résumés in uniform and out. Ford was a Force Recon Marine with combat tours in the Gulf War, Somalia, Iraq, and Afghanistan before moving into high-end security contracting. Chiasson was a Navy Hospital Corpsman and Texas paramedic who'd spent years providing high-risk medical support on PSD and convoy details in Iraq and Afghanistan. When the private security firm SOC (Special Operations Consulting) expanded its mobile operations in Afghanistan, both men ended up on armored Ford F-550 gun trucks running some of the most dangerous roads in the country. At first, their teams hauled critical supplies—ammo, fuel, food, equipment—to isolated Special Forces sites and small outposts the regular military couldn't cover. Then SOC picked up the Department of Defense contract to move something that sounded almost ordinary: the mail. Ford, Chiasson, and their teammates suddenly became the unofficial “Pony Express” of Afghanistan, hauling letters and care packages from Kabul and Bagram along the notorious Ring Road to places like Ghazni, Sharana, Orgun-E, and tiny dirt compounds with nothing but Hesco walls and a few tents. Troops took the mail for granted; few ever thought about the chain of convoys and gun trucks that got a letter from a stateside mailbox to a cot in Kandahar. Postcards Through Hell tells that story from the inside. The “Pony Express” ran four teams in a three-on, one-off rotation so three could be on the road at any time. One team took the long hauls, another ran the shorter Kabul ring route while standing QRF, and a third trained, refit, and got ready to swap in. A “good” day might mean an 18-hour, thousand-kilometer push with no major incidents—what they jokingly called the “Thousand Kilometer Club.” Most days weren't like that. They drove flat-bottom F-550s with level-seven armor and twin turrets, strong against small arms but vulnerable to anything placed directly underneath. Once the Taliban figured out that weakness, a well-buried mine or IED under the chassis could flip a truck or tear it in half. The book is anchored in specific days and events. Ford saved incident reports, op orders, and run paperwork; Chiasson kept a journal. Together they rebuilt a timeline that lets them write, “On April 30 we were here; on May 1 this happened,” instead of “sometime that spring.” Around those convoy stories they layer the wider war: the Camp Chapman suicide bombing; Special Forces “kill teams” at outposts like Ramrod; Italian forces paying the Taliban not to attack them, which meant somebody else—often the Pony Express—became the target. They were there when other contractor convoys got hit, when friends died in F-550s blown apart by stacked anti-tank mines, and when gun trucks limped back into Kabul with wounded men inside and burned-out hulks left behind on the road. Their daily life was built around a simple idea: keep your brothers alive. When they weren't running missions, they were on QRF. When they weren't on QRF, they were working out. When they weren't working out, they were training. They ate together, lived on top of each other in cramped villas and compounds, and used the long Afghan “fighting season”—April through October—to sort out who really belonged there. The easy-sounding mail run weeded people out fast. Some new hires lasted one fighting season, some one mission, some one week. Others stayed for years, until they hit what Ford calls “the wall”—that private moment when you look at a body on a slab, or feel age and accumulated blast damage catching up with you, and decide it's time to go home. Postcards Through Hell doesn't ignore the business side of contracting. Ford and Chiasson talk frankly about companies weighing the cost of vehicle upgrades against death-benefit payouts, replacing seasoned expatriate drivers with cheaper local nationals, and relying on Afghan “expediters” whose loyalties sometimes ran in more than one direction.  The story doesn't end when the convoys stop. The contract itself ran, under different companies, into 2016, and Ford and Chiasson had to cut whole chapters from the book because of classified work and units involved.  At heart, Postcards Through Hell is a book about a very unglamorous, absolutely vital piece of America's longest war.  We're grateful to UPMC for Life  for sponsoring this event!

Today's guest is Dr. Kathryn Torok, a pediatric rheumatologist at the University of Pittsburgh and UPMC Children's Hospital of Pittsburgh, where she directs the Pediatric Craniofacial Scleroderma Clinic. Scleroderma in children is rare, about five in 100,000 develop localized disease, and only about one in a million develop systemic disease. It's crucial to treat to target as early as possible. I learned so much from Dr. Torok about how scleroderma affects children and the best approaches to care.

Join us for an evening with Colonel Chuck Bechtel, whose new memoir, Sent to War, Returning for Peace: My Reconciliation with the Vietnam War, traces a long soldier's journey from the jungles of Vietnam to a quiet reckoning half a century later. Chuck was drafted in 1966, a kid from Pennsylvania who suddenly found himself leading a 43-man infantry platoon with the 1st Cavalry Division (Airmobile) in 1968–69. His book tells that story—training, combat, fear, loss, and the strange return home to a country that didn't know what to make of its soldiers. But it also reaches beyond the war. Chuck writes about the decades that followed, the invisible weight so many veterans carried, and the hard work of finding peace in the long after. A centerpiece of the memoir is his return trip to Vietnam in 2022 with his wife and a small group of veterans organized by Mrs. Lei Williams, whose own life was shaped by the war. That journey—walking old ground with former enemies and longtime friends—became a turning point. The book captures the tenderness, the surprises, and the healing that can happen when you're finally ready to face the past. Over thirty-five years in uniform, Chuck rose from Private E-1 to full Colonel, commanded at every level from company to brigade, deployed during Desert Storm, and later played a key role in building the Army's 56th Stryker Brigade Combat Team. His record includes the Bronze Star with “V” for valor, Air Medal, Vietnamese Cross of Gallantry, Combat Infantry Badge, Legion of Merit, and many more. After retiring, he continued serving as a volunteer Ambassador for Veterans' Outreach of PA, helping launch Veterans Grove, a 24/7 therapeutic community for unhoused veterans. Ten percent of his book royalties support that mission. Chuck lives in Hershey, Pennsylvania, with his wife Joan. They have two children and three grandchildren. This livestream will be a conversation not just about a war, but about what it means to come home from one—and how reconciliation can grow, even decades later. We hope you'll join us. We're grateful to UPMC for Life  for sponsoring this event!

Marty has Dr. Donald Yealy (Chief Medical officer UPMC) on to talk about hepatitis B vaccine and children. Council woman Theresa Kail-Smith talks about Pittsburgh's' budget and taxes. Marty also shares a Christmas preparation story.

In this episode, Chris Carmody, SVP and CTO of UPMC, discusses the health system's journey toward a single Epic instance, including the technological and organizational hurdles of wave one of the UPMC Bridges project. He shares lessons learned, how UPMC approaches integrating newly acquired sites, and what sets their large scale consolidation apart as they prepare for Wave Two.

Join us for a special Veterans Breakfast Club Monday Night Livestream on November 24 marking the 58th anniversary of the Battle of Dak To, one of the fiercest and bloodiest engagements of the Vietnam War. We'll be joined by veterans who fought there—men who endured the steep jungle slopes, relentless artillery, and desperate close-quarters combat of the Central Highlands in November 1967. Their firsthand stories will bring to life the courage, chaos, and sacrifice that defined this pivotal and horrific battle. The Battle of Dak To took place in Kon Tum Province, near the border with Laos, as U.S. Army units—mainly from the 173rd Airborne Brigade, 4th Infantry Division, and 1st Cavalry Division—clashed with well-entrenched North Vietnamese Army (NVA) forces. For weeks, paratroopers and infantrymen fought for control of jungle-covered ridges like Hill 875, where heavy bombardment turned the forest to ash and cost hundreds of American lives. By the time the battle ended, over 280 Americans were killed and more than 900 wounded, while NVA losses numbered in the thousands. It was a pyrrhic victory that revealed both the extraordinary valor of U.S. troops and the brutal futility of the wider war. In this livestream, veterans of Dak To will share their memories of combat, loss, and survival—and reflect on what the battle means today, nearly half a century later. We'll explore the human dimension behind the headlines: the fear, the brotherhood, and the haunting aftermath carried home. Join us for an evening of remembrance and reflection as we honor those who fought at Dak To and keep their stories alive. We're grateful to UPMC for Life  for sponsoring this event!

Happy Thursday everyone! Every week we ask the public if they have a topic in mind, and this week you delivered! Amy Gibbons, a Gaelic football player and coach, reached out to us about her 3rd ACL rupture. She is a major advocate for research into why ACL injuries are so prevalent in women's sports, and what can be done to mitigate it. We spoke to her about her own journey and recovery, as well as rugby player Aoibheann Reilly, Kildare football lead s&c Dr Neil Welch, and UPMC consultant orthopaedic surgeon Professor Brian Devitt for this special episode.Have a topic or thought in mind? Send us a DM on @offtheball on all our social platforms or send us a WhatsApp at 087 9 180 180!

Happy Thursday everyone! Every week we ask the public if they have a topic in mind, and this week you delivered! Amy Gibbons, a Gaelic football player and coach, reached out to us about her 3rd ACL rupture. She is a major advocate for research into why ACL injuries are so prevalent in women's sports, and what can be done to mitigate it. We spoke to her about her own journey and recovery, as well as rugby player Aoibheann Reilly, Kildare football lead s&c Dr Neil Welch, and UPMC consultant orthopaedic surgeon Professor Brian Devitt for this special episode.Have a topic or thought in mind? Send us a DM on @offtheball on all our social platforms or send us a WhatsApp at 087 9 180 180!

Happy Thursday everyone! Every week we ask the public if they have a topic in mind, and this week you delivered! Amy Gibbons, a Gaelic football player and coach, reached out to us about her 3rd ACL rupture. She is a major advocate for research into why ACL injuries are so prevalent in women's sports, and what can be done to mitigate it. We spoke to her about her own journey and recovery, as well as rugby player Aoibheann Reilly, Kildare football lead s&c Dr Neil Welch, and UPMC consultant orthopaedic surgeon Professor Brian Devitt for this special episode.Have a topic or thought in mind? Send us a DM on @offtheball on all our social platforms or send us a WhatsApp at 087 9 180 180!

Happy Thursday everyone! Every week we ask the public if they have a topic in mind, and this week you delivered! Amy Gibbons, a Gaelic football player and coach, reached out to us about her 3rd ACL rupture. She is a major advocate for research into why ACL injuries are so prevalent in women's sports, and what can be done to mitigate it. We spoke to her about her own journey and recovery, as well as rugby player Aoibheann Reilly, Kildare football lead s&c Dr Neil Welch, and UPMC consultant orthopaedic surgeon Professor Brian Devitt for this special episode.Have a topic or thought in mind? Send us a DM on @offtheball on all our social platforms or send us a WhatsApp at 087 9 180 180!

Glenn Flickinger and Todd DePastino discuss the VBC's WWII Tour of Italy in October 2026, where they will spend 14 days following the path of the Allied forces through one of the most grueling campaigns of World War II. Todd and Glenn will also talk with Italian Campaign expert, 45th Infantry Division Historian Professor David D'Andrea, who will also be joining us on our trip. We'll trace the course of the Italian Campaign, beginning with Operation Husky, the massive Allied invasion of Sicily in July 1943 that opened the road to Europe's soft underbelly. From the hard-fought landings at Gela and Scoglitti to the urban battles in Palermo and the mountainous defenses near Messina, Sicily tested the courage and coordination of American and British troops. From there, the campaign moved to mainland Italy, first at Salerno, where American soldiers fought to hold their beachhead against fierce counterattacks, and then up the rugged spine of the Apennines. We'll visit key battlegrounds of Cassino, where Allied forces waged a costly struggle for control of the ancient Abbey of Monte Cassino, and Anzio, where troops endured months of shelling in a desperate bid to outflank German defenses. The campaign culminated in the liberation of Rome on June 4, 1944, two days before D-Day in Normandy. Our trip will visit these storied sites—Catania, Syracuse, Agrigento, Palermo, Salerno, Cassino, Anzio, and Rome—accompanied by historians and local guides who will help us connect the landscape to the history that unfolded there. Along the way, we'll also enjoy the beauty that drew the world to Italy long before and long after the war: the turquoise waters of the Amalfi Coast, the golden temples of Agrigento, and the ancient beauty of Palermo and Rome. We're grateful to UPMC for Life  for sponsoring this event!

Recorded live at Abridge's Executive Summit at the Becker's 10th Annual Health IT + Digital Health + RCM Conference, this panel features Chris Carmody of UPMC, Misti Foust-Cofield of Reid Health, and Justin Brueck of Endeavor discussing how AI and ambient technology are reducing burnout, improving clinician satisfaction, and reshaping the future of patient care.This episode is sponsored by Abridge.

Marty talks about what UPMC does to assist veterans

For the 250th birthday of the United States Marine Corps, the Veterans Breakfast Club goes deep with Marine Corps veteran and classical scholar Dr. Josh Cannon about the ancient truths of war. Join this conversation with an  Iraq veteran, anthropologist, and author, whose new book Fatal Second Helen: A Modern Veteran's Iliad bridges the 2,600-year-old world of Homer's Iliad with the modern battlefield of Iraq. Cannon served as an Arabic cryptologic linguist with the Marine Corps from 2000 to 2005, deploying twice to Iraq—first with the invasion in 2003 and again in 2004. After his service, he pursued graduate studies in linguistics and archaeology at the University of Chicago, earning a PhD in Near Eastern Languages and Civilizations. Now a faculty member at the University of Pittsburgh, Cannon brings both the scholar's lens and the veteran's heart to Homer's tale of rage, loss, and honor. In Fatal Second Helen, Cannon retells Homer's epic in clear, vivid prose, weaving in his own combat experiences and reflections on the warrior's life. It's a book that asks timeless questions: What draws people to war? What do they bring back from it? And what can ancient heroes like Achilles teach modern warriors about grief, pride, and the search for meaning? As Cannon writes in his essay “Glorious But Dead—Was It Worth It?”, he has lived the same paradox Homer captured 26 centuries ago: the beauty and the tragedy of battle, the brotherhood and the loss, the impossible attempt to make sense of it all. This conversation promises to be part literary journey, part war story, and part meditation on how veterans across millennia have wrestled with the same enduring human truths. We're grateful to UPMC for Life  for sponsoring this event!

Join the Veterans Breakfast Club for an open and wide-ranging virtual conversation about the military experience, past and present. We believe every veteran has a story to tell and wisdom to share. This event is a chance to listen, learn, and connect with others who understand the unique bonds and challenges of military service. If you have something on your mind—whether a personal memory, a question, or a topic you think deserves attention—we encourage you to bring it to the conversation. Veterans are also invited to email Shaun Hall at shaun@veteransbreakfastclub.org with any specific topics or issues they'd like to discuss. The Veterans Breakfast Club's mission is to create communities of listening around veterans and their stories, and our Open Conversations are one of the most dynamic ways we do that. These sessions are often wide-ranging, emotional, funny, and thought-provoking, providing a welcoming space where everyone's voice is valued. This event is free and open to all. To join the conversation live on Zoom, please use this link: https://us02web.zoom.us/j/6402618738. Or tune in on Facebook or YouTube at 7:00pm ET on June 9. Whether you have something to share or simply want to listen and learn, we welcome you to be part of the conversation! We're grateful to UPMC for Life  for sponsoring this event!

Send us a textWhat if rural hospitals could thrive instead of just survive?In this episode of CareTalk Executive Features, WVU Medicine President & CEO Albert L. Wright, Jr. joins host David Williams to share how the health system is redefining rural healthcare, expanding access, advancing innovation, and aligning care delivery through initiatives like Peak Health.

Today's guest is Reverend Eleanor Shell, the founder of Resilient Magnolia. After surviving a traumatic brain injury in 2024, Eleanor began sharing her powerful story of recovery and reflection. She weaves together her background as a pastor, fundraiser, and community builder with her lived experience of healing. Through writing, speaking, and creative projects, Eleanor sparks conversations about what it means to move through bad days, grow in the dark, and bloom anyway. At the heart of her work is a belief that resilience is not about enduring in silence, but about growing authentically and finding new ways to flourish even when life doesn't go according to plan.Summary:In this deeply moving and insightful episode, Bethany Lewis talks with Reverend Eleanor Shell about her life-altering concussion after being hit by a car while walking with her infant daughter. Eleanor shares the shocking and often frustrating journey of getting diagnosed, the "blooming" of her symptoms days after the injury, and the profound impact it had on her identity as a high-achieving professional, community leader, and mother.We discuss:The initial denial and the challenge of getting a proper diagnosis.The drastic shift from being the "franchise player" in her family to being on the "injured reserve."The emotional toll, including depression and the struggle with identity.The treatments and therapies that helped, including intensive programs at the Shepherd Center in Atlanta and UPMC in Pittsburgh.The concept of "resiliency" and how Eleanor redefined it from "bouncing back" to a journey of "sustained growth through honesty, rhythm, and renewal."Practical advice for caregivers and loved ones.Description:What does it truly mean to be resilient after a life-changing event like a brain injury? In this episode of the Concussion Coach Podcast, Bethany Lewis sits down with Reverend Eleanor Shell, who shares her raw and powerful story of surviving a traumatic brain injury. Eleanor opens up about the invisible struggles, the mourning of her former self, and the difficult but beautiful journey of redefining her purpose. She explains her "Resiliency Arc"—a framework for moving through bad days, seasons of endurance, and ultimately finding a way to "bloom anyway." If you or someone you love is navigating a difficult season, whether from a concussion or another life-altering event, this conversation is a beacon of hope, honesty, and practical wisdom. Learn how to move through hardship with authenticity and discover that resilience is a journey, not a destination.Resources & Contact Info Mentioned by Guest:Eleanor's Platforms:Resilient Magnolia on Substack: Where Eleanor writes about resilience, bad days, and her journey. https://resilientmagnolia.substack.com/ (Free subscription available)Resilient Magnolia Website: Find free resources, worksheets, affirmation cards, and more. www.resilientmagnolia.comInstagram (Personal Journey): Follow her ongoing journey at @reclaimingmybrainTreatment Centers & Specialists Eleanor Mentioned:Shepherd Center (Atlanta): Complex Concussion Clinic. https://shepherd.org/treatment/services-clinics/concussion-clinic/UPMC Sports Medicine Concussion Program (Pittsburgh): A leading clinic in concussion treatment. https://www.upmc.com/services/sports-medicine/conditions/concussionOther Helpful Concepts & Tools:Fair Play Method: A system to help couples divide the invisible labor of running a household. https://fairplaylife.com/Automatic Email Response: Eleanor uses an auto-reply to manage communication: "As I continue to recover from my accident, my time on email is limited. Please excuse any delay in response."Podcast Host Contact Information:Bethany Lewis, The Concussion CoachCoaching: Sign up for a free consultation for Bethany's concussion coaching HERE

(00:00:00) Every second counts when it comes to a stroke, says Lauren Swartz, Nurse Navigator with the UPMC Neurological Institute. Ahead of World Stroke Day, Swartz joined The Spark to remind listeners that knowing the warning signs—and acting fast—can save lives. (00:20:24) as spooky season approaches, historian Chrissy Senecal says that monsters were very real to people living in medieval Europe — though not always in the ways we imagine. “In fact, there were,” she said. “Spooky season is my favorite season, and I am so happy to talk about the way that medieval people thought about monsters and how they were different from maybe what we think of as monsters today.”Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

What if a health system could be massive and still feel local to every patient it serves? We sit down with Dr. MaCalus Hogan, chair of orthopedic surgery at UPMC, to unpack how a hybrid model—academic, community-employed, and private partners—can deliver scale without sameness. Dr. Hogan shares the leadership habits that shaped his path (mentorship, humility, listening first) and how those habits translate into practical decisions that align surgeons, hospitals, and health plans around value.We pull back the curtain on horizontal integration—building trust and shared standards across regions—before moving into vertical integration that connects financing, bundles, post-acute care, and data. Dr. Hogan explains how UPMC leveraged CJR-era lessons to create surgeon-built programs for quality and cost, mirrored within a 4M+ member health plan. Expect clear insights on center-of-excellence designations, optimizing post-acute spend, and the realities of TEAMS participation. We also dig into consolidation with eyes wide open: comparing contracts, unlocking economies of scale, and reinvesting savings into community access points like ambulatory surgery centers and subspecialty services where patients actually live.Looking 15–20 years ahead, Dr. Hogan argues the big will get bigger, but winners will collaborate, not copy-and-paste. Markets differ, payer mixes shift, and culture matters. The future favors systems that listen locally and act decisively—standardizing where it helps, flexing where it counts. If you care about orthopedic leadership, bundles, payer alignment, and how to grow without breaking what works, this conversation offers a grounded playbook.Enjoy the episode? Follow, share with a colleague, and leave a review with your biggest takeaway—what's one integration move your market needs next?

This episode recorded live at the 10th Annual Health IT + Digital Health + RCM Annual Meeting features Chris Horvat, Senior Director of Clinical Informatics at UPMC, discussing the leveraging of generative AI and machine learning in healthcare. He also offers advice for emerging leaders on navigating the evolving digital health landscape.

This episode features Dr. Richard Celko, Chief Dental Officer at UPMC Health Plan who discusses challenges with access to dental care in rural areas, strategies for addressing community needs, and insights on current events shaping the dental industry.

Legendary journalist and author Elizabeth Becker, who has spent her career bearing witness to the frontlines of history, joins us to talk about her new book, You Don't Belong Here: How Three Women Rewrote the Story of War ,a riveting account of three trailblazing female correspondents who shattered gender barriers to cover the Vietnam War. The book tells the stories of Frances FitzGerald, Kate Webb, and Catherine Leroy, but Elizabeth herself reported from Cambodia and Vietnam in the 1970s. Her courage and insight—captured in You Don't Belong Here—help redefine how we understand both war and the craft of journalism. We'll also explore Becker's earlier, haunting book, When the War Was Over: Cambodia and the Khmer Rouge Revolution. Drawing on her harrowing reporting in Cambodia, Becker offers an account of the Khmer Rouge's genocide. She became one of only two Western journalists to meet Pol Pot—an experience that forever shaped her understanding of power, propaganda, and human tragedy. That historic meeting has now inspired the new feature film Meeting with Pol Pot (2024), directed by acclaimed Cambodian filmmaker Rithy Panh. The dramatization follows three Western journalists navigating a tightly controlled “Potemkin village” as the regime teeters on the brink of collapse and mass murder is underway behind the scenes. The film, which premiered at Cannes in 2024, brings Becker's gripping firsthand account to life and raises questions about truth, memory, and the moral responsibility of journalists. As the character based on Becker—Lise Delbo, played by Irène Jacob—observes, “Genocide is also about silence. You don't see anything, you don't hear anything.” Elizabeth Becker is a pioneering journalist and author. She began her career as a war correspondent for The Washington Post in Cambodia and later served as The New York Times' Senior Foreign Editor. She has covered politics, economics, and international affairs for decades and is a sought-after commentator and lecturer. Her books—award-winning, deeply reported, and beautifully written—have reshaped how we understand Vietnam, Cambodia, and the role of women in war. Learn more: elizabethbecker.com/about | Reviews We're grateful to UPMC for Life  for sponsoring this event!

This episode recorded live at the 10th Annual Health IT + Digital Health + RCM Annual Meeting features Deepan Kamaraj, Director, Analytics & Informatics, UPMC Enterprises. Kamaraj shares how UPMC is testing and deploying AI responsibly through data governance, closed-container evaluations, and cross-functional collaboration, while offering guidance for leaders balancing innovation, regulation, and operational efficiency.

The Veterans Breakfast Club invites you to join us on Thursday, October 16 at 7:00pm Eastern for a special online conversation with author Brenda Partridge-Brown about her new book, Echoes of a Little Brown Soldier Girl. The program will be held on VBC Zoom and livestreamed to our Facebook and YouTube pages. Brenda's book tells the story of her mother, Willie Belle Irvin-Partridge, who served in the 6888th Central Postal Directory Battalion during World War II. Known as the “Six Triple Eight,” the 6888th was the only all-female, predominantly Black U.S. Army unit sent overseas. Their task was both monumental and essential: to clear a massive backlog of more than 17 million pieces of undelivered mail and restore the flow of letters that sustained morale for American troops in Europe. With the motto “No Mail, Low Morale,” the women of the 6888th completed in just three months what had been expected to take six, all while facing racism, sexism, and the daily challenges of wartime service. Through family memories, archival research, and military records, Brenda Partridge-Brown reconstructs her mother's remarkable story and places it in the broader context of a unit whose achievements remained largely overlooked for decades. She also describes the long struggle to secure public recognition for the 6888th, which culminated in the award of the Congressional Gold Medal in 2022. This program is an opportunity to hear about an extraordinary group of women who made history, and about one daughter's journey to bring her mother's service out of the shadows and into the light. Join us on October 16 as we honor the legacy of the 6888th and listen to the echoes of a “little brown soldier girl” whose courage and devotion deserve to be remembered. We're grateful to UPMC for Life  for sponsoring this event!

Cameron Hill and Michael McCarthy join Eoin Sheehan to discuss today's news before the Republic of Ireland face off against Armenia in a do or die World Cup Qualifier in the Aviva Stadium The Newsround is brought to you by UPMC #getbackinaction

Pirates baseball ended poorly and quietly, but Penguins hockey is just getting started! The Pens are bringing back a beloved player, goalie Marc-Andre Fleury, for a one-night-only, send-off party at Saturday's game. There's an idea to build a private helipad in the city, City Council agreed to spend $1.8 million on a plan for the proposed public safety training center in Lincoln-Lemington, and Kamala Harris is spilling the tea on why she didn't pick PA Gov. Josh Shapiro to be her running mate last year. Plus, Pittsburgh's iffy finances got dealt another blow over the jock tax this week, and parents of local trans kids have filed a complaint with the state against UPMC over their policy to end gender-affirming care for their children. Won't you be our Neighbor? Sign up ASAP to get a limited edition tote bag + a chance to win free tickets to Say Cheese! at Mazzotta Winery and the Rock and Roll Hall of Fame in Cleveland. Notes and references from today's show: Pittsburgh City Council approves first step toward public-safety campus on VA hospital site [WESA] Pittsburgh to spend $1.8M on master plan for controversial public safety training center [TribLive] PODCAST: Why Pittsburgh's Divided Over Possible 'Cop City' [City Cast Pittsburgh] PODCAST: The Fight To Get a Gun Range Out of Highland Park [City Cast Pittsburgh] Trans patients file discrimination complaint against UPMC over termination of gender-affirming care [WESA] Trans Patients File Groundbreaking Legal Complaint Against UPMC For Capitulation To Trump [Erin In The Morning] Parents to UPMC: Tell us whether you're giving our trans kids' records to the feds [PublicSource] Anti-Trans National Legal Risk Assessment Map: August Edition [Erin In The Morning] Kamala Harris opens up about Joe Biden's weird Philly phone call, Josh Shapiro's VP interview, and more [Philadelphia Inquirer] 5 takeaways from Kamala Harris' new book about her sprint for the presidency [NPR] State Supreme Court calls foul on Pittsburgh's 'jock tax,' adding to city's financial headaches [WESA] PODCAST: Is Pittsburgh Going Broke? [City Cast Pittsburgh] Penguins release more tickets for Marc-Andre Fleury exhibition game [WPXI] Bucs Limp to the Finish in Another Lost Season [Pittsburgh Magazine] No place to land: Pittsburgh's lack of private helipads sparks new initiative [Pittsburgh Business Times] Learn more about the sponsors of this September 26th episode: Carnegie Library of Pittsburgh Heinz History Center Planned Parenthood of Western PA City Cast Neighbors - Now through Oct. 3 when you sign up you get this awesome tote that says Neighbors Make Pittsburgh Babbel - Get up to 55% off at Babbel.com/CITYCAST Want more Pittsburgh news? Sign up for our daily morning Hey Pittsburgh newsletter. We're also on Instagram @CityCastPgh! Interested in advertising with City Cast? Find more info here.

In this episode, Scott Becker covers five major healthcare stories, including UPMC's talks to acquire three Ohio hospitals, concerns over Trump's new H-1B visa fee, potential impacts of Medicaid work requirements, and more.

In this episode, Scott Becker discusses UPMC's rise as the fifth largest nonprofit health system in the U.S., with 40 hospitals, $29 billion in revenue, and 100,000 employees.

In this episode, Mandy Fauble, PhD, LCSW, Vice President of Operations at UPMC Western Behavioral Health, discusses workforce transformation, community partnerships, and the role of technology in expanding access and improving behavioral health services.

In this episode, Brendan Harris, president of UPMC for You and state programs, shares how initiatives like the Pathways to Work program and Neighborhood Centers are addressing social determinants of health, supporting Medicaid members, and strengthening local communities.